Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079106518> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2079106518 abstract "Intranasal delivery provides a practical, noninvasive, method of bypassing the blood–brain barrier to deliver therapeutic agents to the brain and spinal cord. [See Dhanda (2005) Drug Delivery Technology 5(4):64–72 for a review.] Intranasal delivery allows drugs that do not cross the blood–brain barrier to be delivered to the central nervous system (CNS) within minutes. It also directly targets drugs that do cross the blood–brain barrier to the CNS, eliminating the need for systemic delivery and thereby reducing unwanted systemic side effects. Intranasal delivery does not require any modification of the therapeutic agent. A wide variety of therapeutics, including both small molecules and macromolecules are rapidly delivered intranasally to the brain and can target the olfactory and connected memory areas affected by Alzheimer's disease (AD). This is possible because of the unique connection that the olfactory and trigeminal nerves provide between the brain and external environment [Thorne (2004) Neuroscience 127:481–496]. Using the intranasal delivery method, which I first introduced in 1989, researchers in Italy have reversed neurodegeneration and rescued memory in a transgenic mouse model of AD [Capsoni (2002) PNAS 99(19):12432–12437 and De Rosa (2005) PNAS 102(10): 3811–3816]. We and others have demonstrated both treatment of and protection against stroke in animals with intranasal IGF–I [Liu (2004) Journal of Stroke and Cerebrovascular Diseases 13(1): 16–23], deferoxamine [Panter (2005) Society for Neuroscience Abstracts #669.5] and EPO [Yu (2005) Neurosci Lett 387:5]. Researchers in Israel have used intranasal delivery to target NAP and ADNF to the brain to treat anxiety and neurodegeneration [Alcalay (2004) Neuroscience Letters 361:128–131; Gozes (2000) JPET 293(3):1091–1098.] Intranasal NGF and EGF have been shown to stimulate neurogenesis in adult animals [Jin (2003) Ann Neurol 53:405–409]. Our collaborators [Reger (2006) Neurobiology of Aging: in press] have demonstrated that intranasal insulin acutely improves memory in patients with AD and those with mild cognitive impairment while researchers in Germany [Benedict (2004) Psychoneuroimmunol. 29:1326–1334] have shown that eight weeks of intranasal insulin treatment improves both memory and mood in normal adult humans. This new method of delivery can revolutionize the treatment of Alzheimer's disease, stroke, and other brain disorders." @default.
- W2079106518 created "2016-06-24" @default.
- W2079106518 creator A5046805860 @default.
- W2079106518 date "2006-07-01" @default.
- W2079106518 modified "2023-09-27" @default.
- W2079106518 title "S3-04-03: Bypassing the blood-brain barrier with intranasal delivery to treat Alzheimer's disease and related disorders" @default.
- W2079106518 doi "https://doi.org/10.1016/j.jalz.2006.05.182" @default.
- W2079106518 hasPublicationYear "2006" @default.
- W2079106518 type Work @default.
- W2079106518 sameAs 2079106518 @default.
- W2079106518 citedByCount "0" @default.
- W2079106518 crossrefType "journal-article" @default.
- W2079106518 hasAuthorship W2079106518A5046805860 @default.
- W2079106518 hasConcept C126322002 @default.
- W2079106518 hasConcept C127413603 @default.
- W2079106518 hasConcept C142724271 @default.
- W2079106518 hasConcept C15744967 @default.
- W2079106518 hasConcept C169760540 @default.
- W2079106518 hasConcept C178790620 @default.
- W2079106518 hasConcept C185592680 @default.
- W2079106518 hasConcept C2776925932 @default.
- W2079106518 hasConcept C2778402981 @default.
- W2079106518 hasConcept C2779134260 @default.
- W2079106518 hasConcept C2779820397 @default.
- W2079106518 hasConcept C2780645631 @default.
- W2079106518 hasConcept C529278444 @default.
- W2079106518 hasConcept C71924100 @default.
- W2079106518 hasConcept C78519656 @default.
- W2079106518 hasConcept C85663871 @default.
- W2079106518 hasConcept C98274493 @default.
- W2079106518 hasConceptScore W2079106518C126322002 @default.
- W2079106518 hasConceptScore W2079106518C127413603 @default.
- W2079106518 hasConceptScore W2079106518C142724271 @default.
- W2079106518 hasConceptScore W2079106518C15744967 @default.
- W2079106518 hasConceptScore W2079106518C169760540 @default.
- W2079106518 hasConceptScore W2079106518C178790620 @default.
- W2079106518 hasConceptScore W2079106518C185592680 @default.
- W2079106518 hasConceptScore W2079106518C2776925932 @default.
- W2079106518 hasConceptScore W2079106518C2778402981 @default.
- W2079106518 hasConceptScore W2079106518C2779134260 @default.
- W2079106518 hasConceptScore W2079106518C2779820397 @default.
- W2079106518 hasConceptScore W2079106518C2780645631 @default.
- W2079106518 hasConceptScore W2079106518C529278444 @default.
- W2079106518 hasConceptScore W2079106518C71924100 @default.
- W2079106518 hasConceptScore W2079106518C78519656 @default.
- W2079106518 hasConceptScore W2079106518C85663871 @default.
- W2079106518 hasConceptScore W2079106518C98274493 @default.
- W2079106518 hasIssue "3S_Part_2" @default.
- W2079106518 hasLocation W20791065181 @default.
- W2079106518 hasOpenAccess W2079106518 @default.
- W2079106518 hasPrimaryLocation W20791065181 @default.
- W2079106518 hasRelatedWork W2067076937 @default.
- W2079106518 hasRelatedWork W2229489465 @default.
- W2079106518 hasRelatedWork W2319878335 @default.
- W2079106518 hasRelatedWork W2377919880 @default.
- W2079106518 hasRelatedWork W2391967478 @default.
- W2079106518 hasRelatedWork W2794006736 @default.
- W2079106518 hasRelatedWork W2900115693 @default.
- W2079106518 hasRelatedWork W4220732527 @default.
- W2079106518 hasRelatedWork W4361254526 @default.
- W2079106518 hasRelatedWork W2993093859 @default.
- W2079106518 hasVolume "2" @default.
- W2079106518 isParatext "false" @default.
- W2079106518 isRetracted "false" @default.
- W2079106518 magId "2079106518" @default.
- W2079106518 workType "article" @default.